DIVI S LABORATORIES LTD vs INFLUX HEALTHTECH LIMITED

A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and INFLUX HEALTHTECH LIMITED (INFLUX) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, DIVI S LABORATORIES LTD leads DIVISLAB vs INFLUX on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability22
  • Growth02
  • Size & financial health40
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

94.49
P/E ratio
39.36
10.62
P/B ratio
6.48
0.33%
Dividend yield
0.00%
₹96.73
EPS
₹7.37

Profitability

Even

How efficiently each company turns capital and sales into profit. Higher is better.

16.50%
Return on equity
30.00%
22.00%
Return on capital
60.00%
33.00%
EBITDA margin
20.00%
24.32%
Net margin
12.38%

Growth

INFLUX takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
24.55%
12.10%
Profit CAGR (3Y)
42.16%

Size & financial health

DIVISLAB takes 4/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹2.43L Cr
Market cap
₹704 Cr
₹10,560 Cr
Revenue
₹105 Cr
₹2,568 Cr
Net profit
₹13 Cr
0.00
Debt / equity
0.01
DIVI S LABORATORIES LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 14.6 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
INFLUX HEALTHTECH LIMITED
  • + ["Company has reduced debt.", "Company is almost debt free.", "Company has a good return on equity (ROE) track record: 3 Years ROE 39.1%"]
  • ["Though the company is reporting repeated profits, it is not paying out dividend", "Working capital days have increased from 48.1 days to 83.5 days"]
DIVI S LABORATORIES LTD full analysis INFLUX HEALTHTECH LIMITED full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

DIVISLAB vs INFLUX: Share Price, Valuation & Which to Buy | DocStoX